Business Context and Reporting Period
This Form 8-K Current Report was filed by Nemus Bioscience, Inc. (not Skye Bioscience, Inc.) on April 30, 2018. The filing addresses significant changes in executive leadership, specifically the departure of the Chief Financial Officer (CFO) and the appointment of a successor.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The financial data presented is limited to compensation terms associated with executive personnel changes.
- Outgoing CFO Separation Payment: A lump sum gross payment of $145,833.
- Outgoing CFO Benefits: Reimbursement for six months of COBRA coverage.
- Incoming CFO Base Salary: $250,000 annually.
- Incoming CFO Equity Grant: 1% of fully diluted shares (65% options, 35% RSUs).
- Incoming CFO Bonus Potential: Discretionary bonus of 20% to 40% of base salary.
Material Changes
The primary material change reported is the transition of the Chief Financial Officer role:
- Departure: Elizabeth Berecz entered into a separation agreement effective April 30, 2018, with a final separation date of May 25, 2018. She will remain principal financial officer until that date.
- Appointment: Doug Cesario joined the company on April 23, 2018, and is appointed CFO effective May 26, 2018.
Outlook, Risks, and Management Commentary
Management commentary highlights Mr. Cesario's diverse background in finance, including roles at Kaiser Foundation Hospitals, private equity, and investment banking, stating he possesses the requisite expertise for the CFO role. The filing notes that the outgoing CFO has agreed to ongoing cooperation obligations and releases. No specific financial guidance, market risks, or contingencies regarding the company's operations are disclosed in this report.
Investor Verification Checklist
- Verify the exact vesting schedule and strike price for the 1% equity grant awarded to the new CFO.
- Confirm the total cash outflow impact of the $145,833 separation payment and COBRA reimbursement on the company's current liquidity.
- Review the full text of the Separation Agreement (Exhibit 10.1) for any additional restrictive covenants or non-compete clauses.
- Monitor the transition period between May 25 and May 26, 2018, to ensure continuity in financial reporting and operations.